198 related articles for article (PubMed ID: 36449420)
1. Trial of Deferiprone in Parkinson's Disease.
Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
Klopstock T; Tricta F; Neumayr L; Karin I; Zorzi G; Fradette C; Kmieć T; Büchner B; Steele HE; Horvath R; Chinnery PF; Basu A; Küpper C; Neuhofer C; Kálmán B; Dušek P; Yapici Z; Wilson I; Zhao F; Zibordi F; Nardocci N; Aguilar C; Hayflick SJ; Spino M; Blamire AM; Hogarth P; Vichinsky E
Lancet Neurol; 2019 Jul; 18(7):631-642. PubMed ID: 31202468
[TBL] [Abstract][Full Text] [Related]
3. Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG; Remy P; Giordana C; Maltête D; Derkinderen P; Houéto JL; Anheim M; Benatru I; Boraud T; Brefel-Courbon C; Carrière N; Catala H; Colin O; Corvol JC; Damier P; Dellapina E; Devos D; Drapier S; Fabbri M; Ferrier V; Foubert-Samier A; Frismand-Kryloff S; Georget A; Germain C; Grimaldi S; Hardy C; Hopes L; Krystkowiak P; Laurens B; Lefaucheur R; Mariani LL; Marques A; Marse C; Ory-Magne F; Rigalleau V; Salhi H; Saubion A; Stott SRW; Thalamas C; Thiriez C; Tir M; Wyse RK; Benard A; Rascol O;
N Engl J Med; 2024 Apr; 390(13):1176-1185. PubMed ID: 38598572
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
5. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
6. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Deuschl G; Lang AE; Dijkgraaf MGW; de Haan RJ; de Bie RMA;
N Engl J Med; 2019 Jan; 380(4):315-324. PubMed ID: 30673543
[TBL] [Abstract][Full Text] [Related]
7. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
Martin-Bastida A; Ward RJ; Newbould R; Piccini P; Sharp D; Kabba C; Patel MC; Spino M; Connelly J; Tricta F; Crichton RR; Dexter DT
Sci Rep; 2017 May; 7(1):1398. PubMed ID: 28469157
[TBL] [Abstract][Full Text] [Related]
8. Trial of Cinpanemab in Early Parkinson's Disease.
Lang AE; Siderowf AD; Macklin EA; Poewe W; Brooks DJ; Fernandez HH; Rascol O; Giladi N; Stocchi F; Tanner CM; Postuma RB; Simon DK; Tolosa E; Mollenhauer B; Cedarbaum JM; Fraser K; Xiao J; Evans KC; Graham DL; Sapir I; Inra J; Hutchison RM; Yang M; Fox T; Budd Haeberlein S; Dam T;
N Engl J Med; 2022 Aug; 387(5):408-420. PubMed ID: 35921450
[TBL] [Abstract][Full Text] [Related]
9. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
[TBL] [Abstract][Full Text] [Related]
11. Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G; Taylor KI; Anzures-Cabrera J; Marchesi M; Simuni T; Marek K; Postuma RB; Pavese N; Stocchi F; Azulay JP; Mollenhauer B; López-Manzanares L; Russell DS; Boyd JT; Nicholas AP; Luquin MR; Hauser RA; Gasser T; Poewe W; Ricci B; Boulay A; Vogt A; Boess FG; Dukart J; D'Urso G; Finch R; Zanigni S; Monnet A; Pross N; Hahn A; Svoboda H; Britschgi M; Lipsmeier F; Volkova-Volkmar E; Lindemann M; Dziadek S; Holiga Š; Rukina D; Kustermann T; Kerchner GA; Fontoura P; Umbricht D; Doody R; Nikolcheva T; Bonni A; ;
N Engl J Med; 2022 Aug; 387(5):421-432. PubMed ID: 35921451
[TBL] [Abstract][Full Text] [Related]
12. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
13. Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
Wills AM; Li R; Pérez A; Ren X; Boyd J;
J Neurol; 2017 Aug; 264(8):1746-1753. PubMed ID: 28712000
[TBL] [Abstract][Full Text] [Related]
14. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
15. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
[TBL] [Abstract][Full Text] [Related]
16. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.
Negida A; Hassan NM; Aboeldahab H; Zain YE; Negida Y; Cadri S; Cadri N; Cloud LJ; Barrett MJ; Berman B
CNS Neurosci Ther; 2024 Feb; 30(2):e14607. PubMed ID: 38334258
[TBL] [Abstract][Full Text] [Related]
18. Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Devos D; Moreau C; Devedjian JC; Kluza J; Petrault M; Laloux C; Jonneaux A; Ryckewaert G; Garçon G; Rouaix N; Duhamel A; Jissendi P; Dujardin K; Auger F; Ravasi L; Hopes L; Grolez G; Firdaus W; Sablonnière B; Strubi-Vuillaume I; Zahr N; Destée A; Corvol JC; Pöltl D; Leist M; Rose C; Defebvre L; Marchetti P; Cabantchik ZI; Bordet R
Antioxid Redox Signal; 2014 Jul; 21(2):195-210. PubMed ID: 24251381
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
